Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-Driven Nivolumab in Advanced Metastatic NSCLC
NCT03121417Phase 2Withdrawn
- Sponsor
- Emory University
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Emory University. Primary endpoint: Objective Response Rate up to 3 years. Planned start Jul 2017; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03121417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121417.